A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).

Emily G GreengardRobin WilliamsBranden MoriarityXiaowei LiuCharles G MinardJoel M ReidTerrence FisherElizabeth EvansDesa Rae PastoreMaurice ZaudererStephan D VossElizabeth FoxBrenda J Weigel

Published in: Pediatric blood & cancer (2024)

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keyphrases

young adults
healthcare
public health
palliative care
mental health
randomized controlled trial
open label
risk assessment
human health
social media
placebo controlled